ANNX

Annexon Inc

Add to Watchlist

Advanced Chart

2.400

-0.09(-3.614%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.490

Open

2.490

VWAP

Vol

271.43K

Mkt Cap

273.19M

Low

2.375

Amount

EV/EBITDA(TTM)

Total Shares

105.41M

9.49M

EV/OCF(TTM)

P/S(TTM)

Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.365

+10.74%

-0.364

+45.51%

-0.362

+57.2%

Estimates Revision

The market is revising No Change the revenue expectations for Annexon, Inc. (ANNX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 26.32%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+21.17%

In Past 3 Month

Stock Price

Go Up

+26.32%

In Past 3 Month

7 Analyst Rating

383.33% Upside

Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is 11.60 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

383.33% Upside

Current: 2.400

Low

9.00

Averages

11.60

High

14.00

383.33% Upside

Current: 2.400

Low

9.00

Averages

11.60

High

14.00

Wells Fargo

Derek Archila

Overweight

maintain

$14

2025-07-10

Reason

Wells Fargo

Derek Archila

Price Target

$14

2025-07-10

maintain

Overweight

Reason

Wells Fargo analyst Derek Archila spoke to Annexon as the shares traded down earlier today post the circulation of a tweet from a month ago by a physician. A doctor claimed the FDA requested a confirmatory study of tanruprubart in the U.S. as it did not accept the comparison to the International GBS Outcomes Study database as evidence of efficacy in western Guillain-Barre syndrome, the analyst tells investors in a research note. Wells spoke to management, who said the post is not factual. Annexon's CEO noted this post was one week before the company's FDA meeting, Wells points out. The company told the firm that the FDA has not requested another confirmatory trial. After selling off earlier in the day, shares of Annexon are up 2% to $2.82 in afternoon trading. Wells keeps an Overweight rating on the shares with a $14 price target. It recommends buying the shares on weakness.

H.C. Wainwright

Buy

downgrade

$20 -> $14

2025-05-13

Reason

H.C. Wainwright

Price Target

$20 -> $14

2025-05-13

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Annexon to $14 from $20 and keeps a Buy rating on the shares. The firm reduced the stock's multiple and increased its discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk. Annexon announced that it is on track to meet with the FDA for tanruprubart around Q2, the analyst tells investors in a research note.

Needham

Joseph Stringer

Strong Buy

Reiterates

$16

2025-03-04

Reason

Needham

Joseph Stringer

Price Target

$16

2025-03-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$30

2024-12-17

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$30

2024-12-17

Reiterates

Strong Buy

Reason

Needham

Joseph Stringer

Strong Buy

Reiterates

$16

2024-11-15

Reason

Needham

Joseph Stringer

Price Target

$16

2024-11-15

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$30

2024-11-15

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$30

2024-11-15

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Annexon Inc (ANNX.O) is -1.66, compared to its 5-year average forward P/E of -4.43. For a more detailed relative valuation and DCF analysis to assess Annexon Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.43

Current PE

-1.66

Overvalued PE

-1.12

Undervalued PE

-7.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.42

Current EV/EBITDA

-0.17

Overvalued EV/EBITDA

1.68

Undervalued EV/EBITDA

-6.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.05

Current PS

0.00

Overvalued PS

1.90

Undervalued PS

-1.79

Financials

Annual

Quarterly

FY2025Q1

YoY :

+100.91%

-57.41M

Operating Profit

FY2025Q1

YoY :

+115.90%

-54.36M

Net Income after Tax

FY2025Q1

YoY :

+76.19%

-0.37

EPS - Diluted

FY2025Q1

YoY :

+77.34%

-50.13M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.0K

USD

3-6

Months

0.0

USD

6-9

Months

126.4K

USD

0-12

Months

169.7K

USD

Bought

0-3

10.1K

USD

Months

3-6

0.0

USD

Months

6-9

17.1K

USD

Months

0-12

36.6K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

506.6K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.0K

USD

3-6

Months

0.0

USD

6-9

Months

126.4K

USD

0-12

Months

169.7K

USD

Bought

0-3

10.1K

USD

Months

3-6

0.0

USD

Months

6-9

17.1K

USD

Months

0-12

36.6K

USD

Months

ANNX News & Events

Events Timeline

2025-07-24 (ET)

2025-07-24

07:13:27

Annexon completes enrollment in Phase 3 ARCHER II trial

2025-05-19 (ET)

2025-05-19

16:14:09

Annexon presents tanruprubart data at PNS annual meeting

2025-05-12 (ET)

2025-05-12

08:06:54

Annexon sees cash runway into 2H26

News

9.0

07-24Newsfilter

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

8.0

07-10NASDAQ.COM

Noteworthy Thursday Option Activity: ANNX, SPOT, STNG

5.0

06-18Newsfilter

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)